A Phase II Clinical Trial to Evaluate the Efficacy and Safety of QLS1410 Tablets in Patients With Uncontrolled Hypertension Who Are Receiving One or More Background Drug Treatments

Inclusion Criteria:

1. Male or female participants must be ≥ 18 years old.
2. Mean seated SBP ≥ 140 mmHg at Screening and at Baseline.
3. Fulfil the following requirements: have a stable regimen (≥ 4 weeks) of one or more antihypertensive medications at the maximum tolerated dose as determined by the investigator.

Exclusion Criteria:

1. Mean seated systolic blood pressure (SBP)≥ 180 mmHg.
2. Mean seated diastolic blood pressure (DBP)≥ 110 mmHg.
3. Estimated glomerular filtration rate \< 45 mL/min/1.73m2.
4. Serum potassium (K+) level \<3.5 and ≥ 5.0 mmol/L.
5. Concomitant treatment with both ACEI and ARB.
6. Has the following known secondary causes of hypertension: renal artery stenosis, uncontrolled hyperthyroidism, uncontrolled hypothyroidism, pheochromocytoma, Cushing's syndrome, aortic coarctation.
7. NYHA functional heart failure class IV at Screening.